|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
As an elevated expression of HSP90AA1, HSP90AB1, HSP90B1 and TRAP1 was associated with poorer OS outcomes in patients with NSCLC, these HSP90 members may be potential prognostic biomarkers and drug targets for the treatment of NSCLC.
|
30930968 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eleven Hsp90 inhibitors containing an isoxazolonaphtoquinone core were synthesized and evaluated in two MDR models comprised of sensitive and corresponding resistant cancer cells with P-gp overexpression (human non-small cell lung carcinoma and colorectal adenocarcinoma).
|
31527404 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated Hsp90 expression has been linked to poor prognosis in patients with non-small cell lung cancer (NSCLC).
|
31802936 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Luminespib (AUY922) is a second-generation heat shock protein 90 (HSP90) inhibitor with demonstrated activity in non-small cell lung cancer (NSCLC).
|
31446981 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
KCNQ1OT1 presented a positive correlation with HSP90AA1 which predicted the tumor progression in NSCLC from The Cancer Genome Atlas database.
|
30471108 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we report whether Hsp90 inhibitor 17-AAG could enhance salinomycin-induced cytotoxicity in NSCLC cells through modulating TP expression in two non-small-cell lung cancer (NSCLC) cell lines, A549 and H1975.
|
30796972 |
2019 |
|
HSP90AA1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
|
30365122 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hsp90 inhibitors and osimertinib exhibits a good efficiency to inhibit cell viability, colony formation and inhibits expression and activation of proteins involved in osimertinib-resistance and may represent an effective strategy for NSCLC with intrinsic resistance to osimertinib inhibition.
|
31555510 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our insights demonstrate the importance and functional regulation of the HSP90-NAP1 protein complex in cancer metastatic signaling, which spur new avenues to target this interaction as a novel approach to block NSCLC metastasis.
|
30867003 |
2019 |
|
HSP90AA1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
|
29247830 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC.
|
29561705 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this review is to present the data in support of use of HSP90 inhibitors in NSCLC and to provide an overview of the on-going clinical trials involving new-generation HSP90 inhibitors.
|
29521219 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
|
30224681 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Another interesting finding of the study was substantial cytotoxic effects of compounds particularly against lung H1975 (NSCLC) cell lines with IC<sub>50</sub> = 0.26 μM which may be mediated through HSP90 inhibition.
|
29567459 |
2018 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we performed the design, synthesis, and biological evaluation of Hsp90 inhibitors and found that a synthetic small molecule, DPide exerted a potent anticancer activity against TNBC cell line, MDA‑MB‑231 and non‑small cell lung cancer (NSCLC) cell line, H1975 with GI50 values of 0.478 and 1.67 µM, respectively.
|
29436674 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate the capacities of the non-saponin fraction of Panax ginseng and its active principle panaxynol to inhibit Hsp90 function and viability of both non-CSC and CSC populations of NSCLC in vitro and in vivo.
|
29061506 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the feasibility of <sup>89</sup>Zr-labelled one-armed c-MET antibody onartuzumab PET for detecting relevant changes in c-MET levels induced by c-MET-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib resistance or heat shock protein-90 (HSP90) inhibitor NVP-AUY-922 treatment in human non-small-cell lung cancer (NSCLC) xenografts.
|
28315949 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our studies offer a way forward for Hsp90 inhibitors through the rational design of Hsp90 inhibitor combinations that may prevent and/or overcome resistance to Hsp90 inhibitors, providing an effective therapeutic strategy for <i>KRAS</i>-mutant NSCLC.<i></i>.
|
28167505 |
2017 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that compound 1g inhibited the proliferation of gefitinib-resistant non-small cell lung cancer (H1975) cells, downregulated the expression of client proteins of Hsp90 including EGFR, MET, Her2 and Akt, and up-regulated the expression of Hsp70.
|
27770383 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: Several Hsp90 inhibitors have been tested in phase I-III trials, until now none was positive in unselected NSCLC; therefore development of AUY922, ganetespib and retaspimycin was halted.
|
28274158 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we report a novel, multifunctional nanoceria platform loaded with a unique combination of two therapeutic drugs, doxorubicin (Doxo) and Hsp90 inhibitor ganetespib (GT), for the diagnosis and effective treatment of NSCLC.
|
28081601 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual inhibition of the HSP90 and PI3K signaling pathways with sub-therapeutic doses of these combined anticancer drugs may represent a potent treatment strategy for KRAS-mutant NSCLC with intrinsic resistance to PI3K inhibition.
|
28797845 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that N19 may be a potential new-generation TKI or HSP90 inhibitor used for treatment of NSCLC patients who show resistance to current TKI-targeting therapies.
|
27362807 |
2016 |
|
HSP90AA1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dual inhibition of the HSP90 and MEK signaling pathways with sub-therapeutic doses may represent a potent therapeutic strategy to treat KRAS-mutant NSCLC with intrinsic resistance to MEK inhibition and to resolve the toxicity observed upon dual inhibition of AKT and MEK at therapeutic doses in clinical trials.
|
26723875 |
2016 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined treatment of NSCLC cells with sulforaphane plus another HSP90 inhibitor (17-AAG) enhanced the inhibition of EGFR-related signaling both in vitro and in vivo.
|
26036303 |
2015 |